Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2016; 6(2):287-290. doi:10.7150/thno.14400 This issue Cite

Editorial

New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma

Charles Mesguich, Paolo Zanotti-Fregonara, Elif Hindié✉

Service de Médecine Nucléaire, CHU de Bordeaux, LabEx TRAIL, Université de Bordeaux, France

✉ Corresponding author: Pr Elif Hindié, MD, PhD, Service de Médecine Nucléaire, Hôpital Haut-Lévêque, CHU de Bordeaux, 33604 Pessac, France. Tel: +(33)557656838; Fax: +(33)557656839. e-mail: elif.hindiefr

Citation:
Mesguich C, Zanotti-Fregonara P, Hindié E. New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. Theranostics 2016; 6(2):287-290. doi:10.7150/thno.14400. https://www.thno.org/v06p0287.htm
Other styles

File import instruction

Abstract

The management of multiple myeloma has fundamentally changed over the years and imaging techniques able to match the therapeutic advances are now much needed. Although many patients now achieve complete response after first-line treatment, relapse is common. Therefore, it would be important to improve the initial prognostic stratification and to detect minimal residual disease after treatment. 18F-FDG-PET/CT is a useful imaging tool which has a high prognostic value at baseline evaluation and can effectively differentiate active from inactive lesions during induction treatment or after autologous stem-cell transplantation. In combination with biological data, it improves the prediction of relapse. Other PET tracers may soon enter clinical practice and overcome some of the limitations of 18F-FDG, such as the low sensitivity in detecting early bone marrow infiltration. Excellent results with 11C-Methionine are reported by Lapa and colleagues in this issue of the Journal. 11C-Methionine uptake reflects the increased protein synthesis of malignant plasmocytes and correlates well with bone marrow infiltration. Other promising PET ligands include lipid tracers, such as 11C-Choline or 11C-acetate, and some peptide tracers, such as 68Ga-Pentixafor, that targets CXCR4 (chemokine receptor-4), which is often expressed with high density by myeloma cells.

Malignant plasma cells are radiosensitive and thus potentially amenable to systemic radionuclide therapy. Indeed, excellent preclinical results were obtained with radioimmunotherapy targeting CD38. Also, preliminary clinical results with peptides targeting CXCR4 (e.g. 177Lu- or 90Y-Pentixather) are encouraging. Multiple myeloma may represent a renewal of the already strong partnership between hematologists and nuclear medicine physicians.

Keywords: multiple myeloma, PET/CT, 18F-FDG, 11C-methionine, 11C-acetate, prognosis, minimal residual disease, radionuclide therapy, 177Lu, CXCR4, CD38

Citation styles

APA
Mesguich, C., Zanotti-Fregonara, P., Hindié, E. (2016). New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. Theranostics, 6(2), 287-290. https://doi.org/10.7150/thno.14400.

ACS
Mesguich, C.; Zanotti-Fregonara, P.; Hindié, E. New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. Theranostics 2016, 6 (2), 287-290. DOI: 10.7150/thno.14400.

NLM
Mesguich C, Zanotti-Fregonara P, Hindié E. New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. Theranostics 2016; 6(2):287-290. doi:10.7150/thno.14400. https://www.thno.org/v06p0287.htm

CSE
Mesguich C, Zanotti-Fregonara P, Hindié E. 2016. New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. Theranostics. 6(2):287-290.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use